Hvilken er prisen på GSK plc (GSK)

Prisen på GSK plc (GSK) er $51.99

Hva er markedsverdien på GSK plc (GSK)

Markedsverdien på GSK plc (GSK) er $104.42B

GSK plc (GSK) P/B-forhold

GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics, Inc.; Alector, Inc.; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

År	P/B-forhold	Endre
2026 (TTM)	4.98	10.51%
2025	4.51	12.39%
2024	4.02	-8.79%
2023	4.40	-19.38%
2022	5.46	58.21%
2021	3.45	-6.69%
2020	3.70	-37.66%
2019	5.93	-56.31%
2018	13.58	-101.77%
2017	-767.86	-1,506.98%
2016	54.57	420.72%
2015	10.48	-16.42%
2014	12.54	39.48%
2013	8.99	-1.42%
2012	9.12	22.53%
2011	7.44	29.83%
2010	5.73	6.13%
2009	5.40	-20.54%
2008	6.80	14.36%
2007	5.95	-10.28%
2006	6.63	-28.07%
2005	9.21	-6.90%
2004	9.90	-16.16%
2003	11.80	36.40%
2002	8.65	-22.90%
2001	11.22	-6.68%
2000	12.02	0.00%

År

P/B-forhold

Endre

2026 (TTM)

4.98

10.51%

2025

4.51

12.39%

2024

4.02

-8.79%

2023

4.40

-19.38%

2022

5.46

58.21%

2021

3.45

-6.69%

2020

3.70

-37.66%

2019

5.93

-56.31%

2018

13.58

-101.77%

2017

-767.86

-1,506.98%

2016

54.57

420.72%

2015

10.48

-16.42%

2014

12.54

39.48%

2013

8.99

-1.42%

2012

9.12

22.53%

2011

7.44

29.83%

2010

5.73

6.13%

2009

5.40

-20.54%

2008

6.80

14.36%

2007

5.95

-10.28%

2006

6.63

-28.07%

2005

9.21

-6.90%

2004

9.90

-16.16%

2003

11.80

36.40%

2002

8.65

-22.90%

2001

11.22

-6.68%

2000

12.02

0.00%

Selskap	P/B-forhold	Forskjell i P/B-forhold	Land
Eli Lilly LLY.US	33.3372	568.86%	US
AstraZeneca PLC AZN.US	6.0657	21.70%	GB
Johnson & Johnson JNJ.US	7.1931	44.32%	US
AbbVie Inc. ABBV.US	-119.6075	-2,499.73%	US
Novartis AG NVS.US	6.3334	27.07%	CH

Selskap

P/B-forhold

Forskjell i P/B-forhold

Land